Repligen (RGEN) Reports In-Line Q2 EPS, provides guidance
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $167.60 -1.19%
Revenue Growth %: +9.4%
Financial Fact:
(Loss) income from operations: 3.75M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +9.4%
Financial Fact:
(Loss) income from operations: 3.75M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.33, in-line with the analyst estimate of $0.33. Revenue for the quarter came in at $154 million versus the consensus estimate of $154.11 million.
GUIDANCE:
Repligen sees FY2024 EPS of $1.42-$1.49, versus the consensus of $1.45.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
- Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
